Macrolide Resistance of Mycoplasma pneumoniae, South Korea, 2000–2011 - Vol. 19 No. 8 - August 2013 - Emerging Infectious Disease journal - CDC
Table of Contents
Volume 19, Number 8–August 2013
Volume 19, Number 8—August 2013
Macrolide Resistance of Mycoplasma pneumoniae, South Korea, 2000–2011
Mycoplasma pneumoniae is 1 of the most common causes of community-acquired pneumonia in children and young adults (1). Epidemics of mycoplasma pneumonia typically occur every 4–7 years; however, epidemics have occurred every 3–4 years in South Korea (2,3). The first-line treatment for mycoplasma pneumonia is macrolide antimicrobial drugs, but macrolide-resistant infections have been recognized in conjunction with an increase in cases in children in Japan, China, Germany, France, Israel, and the United States (1,4–10). Because of the risk to children administered tetracycline and fluoroquinolone (nonmacrolide drugs), M. pneumoniae resistance to macrolide drugs has critical implications for the treatment of mycoplasma pneumonia in children. This study was conducted to identify the prevalence of macrolide resistance among M. pneumoniae strains isolated from children with lower respiratory tract infections (LRTIs) during 4 consecutive epidemics (2000–2011) in South Korea.